US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Metsera Inc.

27.49

-1.1800-4.12%

Post-market: 27.490.00000.00%18:53 EDT

Volume:391.90K

Turnover:10.85M

Market Cap:2.89B

PE:-3.06

High:29.55

Open:29.24

Low:26.78

Close:28.67

Loading ...

Overview Company News Filings

Metsera Inc. Unveils Promising Clinical Data for MET-097i and Preclinical Insights for MET-233i at American Diabetes Association Scientific Sessions

Guggenheim Keeps Their Buy Rating on Metsera, Inc. (MTSR)

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. -- Barrons.com

Two new option listings and two option delistings on May 22nd

Top Premarket Decliners

MT Newswires Live

Metsera's Q1 Net Loss Narrows

MT Newswires Live

Earnings Flash (MTSR) Metsera Posts Q1 Net Loss $1.03 a Share, vs. FactSet Est of $0.85 Loss

MT Newswires Live

Metsera Q1 2025 EPS $(1.03) Beats $(1.04) Estimate, $588M Cash And Cash Equivalents Support Runway Into 2027

Press Release: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday

Metsera, Inc. Appoints New Board Member and Legal Officer

Metsera Inc. Appoints Jon P. Stonehouse to Board of Directors and Names Matthew Lang as Chief Legal Officer

U.S. Small Caps Close Up; Metsera Top Leaders

BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress

Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share

MT Newswires Live

Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M

MT Newswires Live

Metsera Inc: Completed IPO With Gross Proceeds of Approximately $316.2 Mln, Extending Runway Into 2027

THOMSON REUTERS

Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera, Inc. Approves 2024 Executive Cash Bonuses

Q4 2024 Amneal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MTSR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTSR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTSR\",,,,,undefined,":{"symbol":"MTSR","market":"US","secType":"STK","nameCN":"Metsera Inc.","latestPrice":27.49,"timestamp":1749240000000,"preClose":28.67,"halted":0,"volume":391897,"hourTrading":{"tag":"盘后","latestPrice":27.49,"preClose":27.49,"latestTime":"18:53 EDT","volume":48090,"amount":1322002.92,"timestamp":1749250398940},"delay":0,"floatShares":59974168,"shares":105055538,"eps":-8.989882,"marketStatus":"Market Closed","change":-1.18,"latestTime":"06-06 16:00:00 EDT","open":29.24,"high":29.55,"low":26.78,"amount":10851446.481689,"amplitude":0.096617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.989882,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":28.67,"preHourTrading":{"tag":"盘前","latestPrice":28.66,"preClose":28.67,"latestTime":"09:26 EDT","volume":528,"amount":15114.00792,"timestamp":1749216373071},"postHourTrading":{"tag":"盘后","latestPrice":27.49,"preClose":27.49,"latestTime":"18:53 EDT","volume":48090,"amount":1322002.92,"timestamp":1749250398940},"volumeRatio":0.6109272249068929,"impliedVol":1.0037,"impliedVolPercentile":0.1818},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTSR\",,,,,undefined,":{"symbol":"MTSR","floatShares":59974168,"roa":"-27.09%","roe":"-108.40%","lyrEps":-14.490661,"volumeRatio":0.6109272249068929,"shares":105055538,"dividePrice":0,"high":29.55,"amplitude":0.096617,"preClose":28.67,"low":26.78,"week52Low":12.3,"pbRate":"5.71","week52High":32.8082,"institutionHeld":0,"latestPrice":27.49,"eps":-8.989882,"divideRate":0,"volume":391897,"delay":0,"ttmEps":-8.989882,"open":29.24,"prevYearClose":18,"prevWeekClose":26.72,"prevMonthClose":26.72,"prevQuarterClose":27.22,"fiveDayClose":26.72,"twentyDayClose":24.76,"sixtyDayClose":25.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTSR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541220680","title":"Metsera Inc. Unveils Promising Clinical Data for MET-097i and Preclinical Insights for MET-233i at American Diabetes Association Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2541220680","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541220680?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:30","pubTimestamp":1749123032,"startTime":"0","endTime":"0","summary":"Metsera Inc. Unveils Promising Clinical Data for MET-097i and Preclinical Insights for MET-233i at American Diabetes Association Scientific Sessions. Metsera Inc., a clinical-stage biopharmaceutical company, has announced it will present new research at the 85th Scientific Sessions of the American Diabetes Association. The company will showcase its next-generation obesity portfolio, including clinical and preclinical findings from its lead program, MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist. The presentations will include clinical data from MET-097i's completed Phase 1/2 trial, alongside preclinical data on MET-233i, a monthly, ultra-long acting amylin analog. These presentations aim to highlight Metsera's scalable and differentiated approaches to treating overweight and obesity. Further details about the company's presence at the ADA meeting can be found on their website.Disclaimer: This news brief was created by Public Technologies  using generative a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8X3BLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","MTSR","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","BK4585","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2540930697","title":"Guggenheim Keeps Their Buy Rating on Metsera, Inc. (MTSR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540930697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540930697?lang=en_us&edition=fundamental","pubTime":"2025-06-02 21:16","pubTimestamp":1748870189,"startTime":"0","endTime":"0","summary":"In a report released on May 30, Seamus Fernandez from Guggenheim maintained a Buy rating on Metsera, Inc. (MTSR – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-metsera-inc-mtsr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-metsera-inc-mtsr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR"],"gpt_icon":0},{"id":"2539926025","title":"Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2539926025","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539926025?lang=en_us&edition=fundamental","pubTime":"2025-05-30 02:09","pubTimestamp":1748542140,"startTime":"0","endTime":"0","summary":"After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of weight-loss drugs called amylins is drawing the drug industry's attention and dollars.A couple of multibillion-dollar development deals for amylin drugs were signed this year, and more news will come out at June's scientific session of the American Diabetes Association.GLP-1s have shown impressive benefits beyond weight loss, including benefits for the heart, kidneys and perhaps even the brain. Key questions include whether the amylins help people with diabetes lose more weight than they do on GLP-1s; and whether the amylins have the benefits beyond weight loss that GLP-1s are demonstrating.Like GLP-1s, the amylin class of hormones has attracted many pharma suitors. In March, Roche made a deal worth up to $5.3 billion with Denmark's Zealand Pharma to advance pet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","BK4566","LU0122379950.USD","LU1917777945.USD","LU2089283258.USD","IE00B4R5TH58.HKD","BK4550","LU1934455863.HKD","SG9999015945.SGD","LU0158827948.USD","LU2237443549.SGD","BK4007","LU0820561909.HKD","SGXZ81514606.USD","LU2461242641.AUD","LU0058720904.USD","LU0882574055.USD","BK4516","LU0320765646.SGD","LU2112291526.USD","LU0006306889.USD","LU2106854487.HKD","BK4532","LLY","LU2471134879.HKD","LU1496350502.SGD","LU1720051017.SGD","MTSR","LU0029864427.USD","LU1430594728.SGD","LU1868837136.USD","LU0354030511.USD","LU1366192091.USD","LU0170899867.USD","RHHBY","03165","LU1037948897.HKD","LU0198837287.USD","LU0738911758.USD","LU0820561818.USD","LU1623119135.USD","LU1064131342.USD","LU2750360641.GBP","GPCR","SG9999003800.SGD","IE00BSNM7G36.USD","NVO","LU2237443978.SGD","SG9999001176.USD","LU1244550494.USD"],"gpt_icon":1},{"id":"2537494959","title":"Two new option listings and two option delistings on May 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2537494959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537494959?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:35","pubTimestamp":1747917350,"startTime":"0","endTime":"0","summary":"New option listings for May 22nd include Galaxy Digital Inc. – Class A common stock (GLXY) and Metsera Inc (MTSR). Option delistings effective May ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-two-option-delistings-on-may-22nd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-two-option-delistings-on-may-22nd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR","GLXY","BK4139","BK4135"],"gpt_icon":0},{"id":"2534152220","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2534152220","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534152220?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:46","pubTimestamp":1747053979,"startTime":"0","endTime":"0","summary":"Vivakor  shares were down 60% in recent Monday premarket activity, continuing Friday's loss.Nuvve  shares slipped 40%, erasing the previous session's 144% surge.Pan American Silver  stock fell 8%, a day after it said it agreed to acquire MAG Silver for about $2.1 billion in cash and stock.Metsera  stock was 5% lower after it posted a higher-than-expected Q1 net loss.Dole  shares slipped 2% after it reported lower Q1 adjusted earnings and revenue from a year earlier.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU1223083913.SGD","DOLE","SILmain","BK4588","MTSR","NVVE","VIVK","BK4096","BK4212","LU1223082196.USD","PAAS","BK4210","BK4120","BK4539","BK4144","BK4585"],"gpt_icon":1},{"id":"2534229059","title":"Metsera's Q1 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2534229059","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534229059?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:39","pubTimestamp":1747049964,"startTime":"0","endTime":"0","summary":"Metsera  reported a Q1 net loss Monday of $1.03 per diluted share, narrower than a loss of $1.44 a year earlier.An analyst polled by FactSet expected a loss of $0.85.As of March 31, the company said it had $588.3 million in cash and cash equivalents, and that they would likely finance operations through 2027.Metsera's shares were down 5.6% in recent Monday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2534229176","title":"Earnings Flash (MTSR) Metsera Posts Q1 Net Loss $1.03 a Share, vs. FactSet Est of $0.85 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2534229176","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534229176?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:27","pubTimestamp":1747049244,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q1 Net Loss $1.03 a Share, vs. FactSet Est of $0.85 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2534692226","title":"Metsera Q1 2025 EPS $(1.03) Beats $(1.04) Estimate, $588M Cash And Cash Equivalents Support Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2534692226","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534692226?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:17","pubTimestamp":1747048656,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025MET-233i, a monthly, ultra-long acting amylin analog,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45344066/metsera-q1-2025-eps-1-03-beats-1-04-estimate-588m-cash-and-cash-equivalents-support-runway-into-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR"],"gpt_icon":0},{"id":"2534251872","title":"Press Release: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2534251872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534251872?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025. MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025. MET-097 (,) an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224 is on track, with four-week data for selected lead expected in late 2025. NEW YORK, May 12, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported first quarter 2025 financial results and continued portfolio progress.\"The first quarter of 2025 was a period of focused execution and acceleration at Metsera,\" said Whit Bernard, Chief Executive Officer of Metsera. \"We remain on track to deliver on all of our committed clinical milestones fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","LU2065732104.USD","RA","BK4097","BK4139","PRGS"],"gpt_icon":0},{"id":"2531593477","title":"Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2531593477","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531593477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:36","pubTimestamp":1745937392,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/45070499/honeywell-posts-better-than-expected-q1-earnings-joins-crown-holdings-noble-crane-and-other-big-stocks-moving-higher-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLVT","NBL","KNSA","CCK","HON","NE","CR","EPWK","LZMH","TRS","FOUR","PUMP","CECO","LEG","MTSR"],"gpt_icon":1},{"id":"2531267272","title":"Metsera, Inc. Appoints New Board Member and Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2531267272","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531267272?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:49","pubTimestamp":1745876948,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Metsera, Inc. ( ($MTSR) ). On April 28, 2025, Metsera, Inc. appointed Jon P. Stonehouse to its Board of Directo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metsera-inc-appoints-new-board-member-and-legal-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metsera-inc-appoints-new-board-member-and-legal-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTSR"],"gpt_icon":0},{"id":"2531293258","title":"Metsera Inc. Appoints Jon P. Stonehouse to Board of Directors and Names Matthew Lang as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2531293258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531293258?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:26","pubTimestamp":1745875582,"startTime":"0","endTime":"0","summary":"Metsera Inc. has announced key management changes effective April 28, 2025. Jon P. Stonehouse has been appointed to the Board of Directors and will serve as a Class III director until the 2028 annual meeting. He will also join the Audit Committee. Additionally, Matthew Lang has been named the company's Chief Legal Officer and Secretary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDLc516WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2527514952","title":"U.S. Small Caps Close Up; Metsera Top Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2527514952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527514952?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:21","pubTimestamp":1744662060,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies increased Monday, as the Russell 2000 Index gained 1.1%, and the S&P Small Cap 600 Index was up 1.1%.Among companies with a market value of $1 billion to $6.7 billion, Metsera Inc. was the best performer during the session, surging 30%, followed by MP Materials Corp., which surged 22%. Certara Inc. shares jumped 12%, Diginex Ltd. surged 11%, and shares of Viridian Therapeutics Inc. jumped 11%.Exodus Movement Inc. was the biggest laggard, dropping 11%, followed by shares of Plug Power Inc., which dropped 7.1%. Shares of Kenon Holdings Ltd. dropped 5.7%, Peabody Energy Corp. shares plunged 5.5%, and Innodata Inc. tumbled 5.2%.Major U.S. stock indexes closed up Monday with the Nasdaq Composite Index adding 0.6%. Meanwhile, the S&P 500 Index gained 0.8%, and the Dow Jones Industrial Average added 0.8%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR"],"gpt_icon":0},{"id":"2522795538","title":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522795538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522795538?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:44","pubTimestamp":1742989499,"startTime":"0","endTime":"0","summary":"BRIEF-Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio ProgressMarch 26 (Reuters) - Metsera Inc MTSR.O:METSERA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTSR"],"gpt_icon":1},{"id":"2522187964","title":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187964?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:24","pubTimestamp":1742988265,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR"],"gpt_icon":0},{"id":"2522935879","title":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935879?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:23","pubTimestamp":1742988224,"startTime":"0","endTime":"0","summary":"Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTSR","TSS"],"gpt_icon":0},{"id":"2522820423","title":"Metsera Inc: Completed IPO With Gross Proceeds of Approximately $316.2 Mln, Extending Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2522820423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522820423?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986837,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA92XKL3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2522829878","title":"Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522829878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522829878?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025. Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1. Oral formulation optimization study on track to support initiation of clinical trials for MET-224 and MET097 , with MET-224 data expected in late 2025. Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027. NEW YORK, March 26, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress.With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be anot","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IPO","LU2065732104.USD","BK4097","PRGS","MTSR","RA"],"gpt_icon":0},{"id":"2518783956","title":"Metsera, Inc. Approves 2024 Executive Cash Bonuses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783956","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518783956?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:33","pubTimestamp":1741638825,"startTime":"0","endTime":"0","summary":"Metsera, Inc. ( ($MTSR) ) just unveiled an update. On March 7, 2025, Metsera, Inc. announced that its Board of Directors approved the 2024 annual c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metsera-inc-approves-2024-executive-cash-bonuses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTSR","BK4139"],"gpt_icon":0},{"id":"2516530651","title":"Q4 2024 Amneal Pharmaceuticals Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2516530651","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516530651?lang=en_us&edition=fundamental","pubTime":"2025-03-01 18:02","pubTimestamp":1740823351,"startTime":"0","endTime":"0","summary":"Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc.Anastasios Konidaris; Chief Financial Officer, Executive Vice President; Amneal Pharmaceuticals Inc.Joe Renda; Senior Vice President, Chief Commercial Officer-Specialty; Amneal Pharmaceuticals Inc.Jason Daly; Senior Vice President, Chief Legal Officer, Corporate Secretary; Amneal Pharmaceuticals Inc.Thank you, Tony. Good morning, everyone. At Amneal, we're much more than another generics company. We are an American biopharmaceutical company with a track record of excellence in delivering high-quality complex pharmaceuticals at speed and scale. We are a leader in an essential industry, providing millions of patients with access to affordable and innovative medicines. 2024 was an exceptional year where Amneal delivered stellar financial performance with double-digit revenue and adjusted EBITDA growth and reducing net leverage below 4 times. All segments grew revenues double digits. This ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-amneal-pharmaceuticals-inc-100231626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTSR"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTSR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"MTSR","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-03-26","symbol":"MTSR","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742961600000,"reportTimeType":"pre","actualEps":-3.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTSR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTSR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTSR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTSR","date":"2025-06-06","current":-11.330119,"percent":0.650602,"low":-55.8522,"twenty":-17.863854,"median":-12.078462,"eighty":-10.380871,"high":-6.570442,"avg":-13.981783,"sd":5.886319,"marketCap":3011942274},"quantilePoints":[{"date":"2025-02-07","current":-17.973411,"twenty":-17.939327,"median":-17.8882,"eighty":-17.837073,"marketCap":3042628924},{"date":"2025-02-14","current":-18.277736,"twenty":-18.639274,"median":-18.277736,"eighty":-17.958804,"marketCap":3094146515},{"date":"2025-02-21","current":-19.257661,"twenty":-19.263748,"median":-18.612493,"eighty":-17.973411,"marketCap":3260033158},{"date":"2025-02-28","current":-15.222317,"twenty":-19.263748,"median":-18.292952,"eighty":-17.802989,"marketCap":2576909901},{"date":"2025-03-07","current":-16.749262,"twenty":-19.257661,"median":-17.973411,"eighty":-16.634383,"marketCap":2835398748},{"date":"2025-03-14","current":-15.094245,"twenty":-18.72205,"median":-17.767653,"eighty":-15.847091,"marketCap":2555229332},{"date":"2025-03-21","current":-17.309229,"twenty":-18.72205,"median":-17.732316,"eighty":-15.847091,"marketCap":2930192911},{"date":"2025-03-28","current":-15.074845,"twenty":-18.72205,"median":-17.767653,"eighty":-15.847091,"marketCap":3152557072},{"date":"2025-04-04","current":-10.624224,"twenty":-18.709149,"median":-17.433667,"eighty":-15.417782,"marketCap":2221812131},{"date":"2025-04-11","current":-6.570442,"twenty":-18.612493,"median":-16.926585,"eighty":-14.065167,"marketCap":1374056864},{"date":"2025-04-17","current":-8.815846,"twenty":-18.585291,"median":-16.597864,"eighty":-11.231036,"marketCap":1843631343},{"date":"2025-04-25","current":-10.639294,"twenty":-18.362232,"median":-16.039969,"eighty":-10.465489,"marketCap":2224963638},{"date":"2025-05-02","current":-11.734368,"twenty":-18.283822,"median":-15.629326,"eighty":-9.926993,"marketCap":2453973115},{"date":"2025-05-09","current":-12.437626,"twenty":-18.170614,"median":-15.417782,"eighty":-10.4896,"marketCap":2601043422},{"date":"2025-05-16","current":-10.120836,"twenty":-18.143134,"median":-15.084545,"eighty":-9.926993,"marketCap":2690472328},{"date":"2025-05-23","current":-11.083125,"twenty":-18.007321,"median":-13.673351,"eighty":-10.08689,"marketCap":2946282563},{"date":"2025-05-30","current":-10.903313,"twenty":-17.962456,"median":-12.437626,"eighty":-10.237022,"marketCap":2898482293},{"date":"2025-06-06","current":-11.330119,"twenty":-17.863854,"median":-12.078462,"eighty":-10.380871,"marketCap":3011942274}],"updateTime":1749347039547}}}